MARKET

VTRS

VTRS

Viatris Inc Ord Shs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.82
-0.23
-1.35%
Pre Market: 16.85 +0.03 +0.18% 04:59 12/01 EST
OPEN
17.03
PREV CLOSE
17.05
HIGH
17.16
LOW
16.80
VOLUME
403
TURNOVER
--
52 WEEK HIGH
23.11
52 WEEK LOW
12.75
MARKET CAP
20.71B
P/E (TTM)
32.69
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied to difficulties the agency has had in inspecting facilities where investigational drugs are being manufactured, amid COVID-19-related restrictions.
Benzinga · 2d ago
Statement Pursuant to Section 19(a) of the Investment Company Act of 1940: DEX
Business Wire · 3d ago
How a Restructured Pfizer Will Pay Out Its Dividend
The company has said it will adjust its dividend downward next year, by the amount of the dividend investors will get from their new holdings of Viatris.
Barrons.com · 5d ago
Viatris Announces FDA Tentative Approval Of A Pediatric Formulation Of Dolutegravir Under PEPFAR
Viatris Inc. Announces FDA Tentative Approval of a Pediatric Formulation of Dolutegravir (DTG) Under PEPFAR PITTSBURGH, Nov. 23, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a new kind of
Benzinga · 11/23 20:37
Viatris Inc. Announces FDA Tentative Approval of a Pediatric Formulation of Dolutegravir (DTG) Under PEPFAR
Viatris Inc. (NASDAQ: VTRS), a new kind of healthcare company, today announced tentative approval from the U.S. Food and Drug Administration (FDA) for a New Drug Application for pediatric dolutegravir tablets for oral suspension, 10 mg. The new formulation is a result of a collaboration with ViiV Healthcare, the Clinton Health Access Initiative and Unitaid to help expand access to children living with HIV/AIDS in low- and middle-income countries. Tentative approval was granted under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) which permits products that are not approved for marketing in the U.S. because of patent protection or other marketing restrictions to be distributed in other countries where they are critically needed.
PR Newswire · 11/23 20:34
Goldman Sachs Reinstates Buy on Viatris, Announces $22 Price Target
Goldman Sachs analyst Nathan Rich reinstates Viatris (NASDAQ:VTRS) with a Buy and announces $22 price target.
Benzinga · 11/19 13:26
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VTRS. Analyze the recent business situations of Viatris Inc Ord Shs through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VTRS stock price target is 21.56 with a high estimate of 27.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 2.66K
Institutional Holdings: 4.30B
% Owned: 349.35%
Shares Outstanding: 1.23B
TypeInstitutionsShares
Increased
1.14K
115.40M
New
258
4.25M
Decreased
932
212.92M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VTRS
Viatris Inc., formerly Upjohn Inc., is a healthcare company. It is a scientific, manufacturing and distribution company that is specialized in delivering medicines to patients in over 165 countries and territories. It provides access to medicines, advance sustainable operations, develop solutions and leverage it's specializatiin to connect people to products and services through it's Global Healthcare Gateway. It's portfolio comprises of more than 1,400 molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, global brands, complex generic and branded medicines, portfolio of biosimilars and a variety of over-the-counter consumer products. It produces medicines for patients across a broad range of therapeutic areas, spanning both noncommunicable and infectious diseases, which include cardiovascular, oncology, immunology, women’s healthcare, diabetes and metabolism, gastroenterology, respiratory and allergy and dermatology.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Viatris Inc stock information, including NASDAQ:VTRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTRS stock methods without spending real money on the virtual paper trading platform.